drugset / Trial / NCT02091492

Teriparatide for Fracture Repair in Humans

NCT02091492

Phase 3 Withdrawn Medical University of Vienna
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will test the hypothesis that daily subcuaneous administration of 20µg of teriparatide (TPTD) as compared to daily subcuaneous placebo for twelve weeks accelerates proximal 2-segment humerus fracture healing and improves the three dimensional structural properties of bone as measured via quantitative bone image analysis and finite element modeling assessed by quantitative computed tomography.

Timeline

Start
2014-06
Primary completion
2015-09
Completion
2015-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Teriparatide Protein / enzyme biologic 20 ug Subcutaneous

Indications